Login / Signup

Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer.

Meng-Chin HoYing-Shan ChungYu-Ching LinMing-Szu HungYu-Hung Fang
Published in: OncoTargets and therapy (2022)
The concurrent use of PPIs was associated with lower OS in patients with EGFR-mutant lung cancer under the first-line afatinib treatment but not associated with TTF.
Keyphrases
  • epidermal growth factor receptor
  • small cell lung cancer
  • advanced non small cell lung cancer
  • tyrosine kinase
  • wild type
  • squamous cell carcinoma
  • radiation therapy